Inflammation-suppressing composition including peptide
An oligopeptide having a good anti-inflammation effect on microglia has been found, and based on this finding, a composition to be used for suppressing the inflammation of microglia is provided. Inflammation suppression action of a dipeptide has been comprehensively analyzed using the proinflammatory cytokine production of microglia as an indicator. As a result, it has been revealed that an oligopeptide including the sequence LH, DV or MH has a good inflammation suppression effect. The composition containing any of these oligopeptides can provide a composition having the effect of suppressing the excessive inflammatory action of microglia.
1. A method of suppressing microglial-mediated inflammation, comprising administering, to a subject in need of such suppression, a peptide, or a pharmaceutically acceptable salt or a solvate thereof, wherein the amino acid sequence of said peptide consists of the amino acid sequence Leu-His.
2. A method of relieving or treating a symptom of chronic fatigue syndrome, cognitive impairment, or mood disorder, comprising administering, to a subject in need of such relief or treatment, a peptide, or a pharmaceutically acceptable salt or a solvate thereof, wherein the amino acid sequence of said peptide consists of the amino acid sequence Leu-His.
3. A method of relieving a condition caused by stress, comprising administering, to a subject in need of such relief, a peptide, or a pharmaceutically acceptable salt or a solvate thereof, wherein the amino acid sequence of said peptide consists of the amino acid sequence Leu-His.
4. The method according to claim 3 , wherein the condition caused by stress is accompanied by a lack or decrease of willingness, motivation, or vitality to make a voluntary action.
5. The method according to claim 1 , wherein the administration of said peptide, pharmaceutically acceptable salt, or solvate thereof, is performed orally.
6. The method according to claim 2 , wherein the administration of said peptide, pharmaceutically acceptable salt, or solvate thereof, is performed orally.
7. The method according to claim 3 , wherein the administration of said peptide, pharmaceutically acceptable salt, or solvate thereof, is performed orally.
8. The method according to claim 4 , wherein the administration of said peptide, pharmaceutically acceptable salt, or solvate thereof, is performed orally.
9. The method according to claim 1 , wherein said peptide, pharmaceutically acceptable salt, or solvate thereof, is administered in a form of a food or drink.
10. The method according to claim 2 , wherein said peptide, pharmaceutically acceptable salt, or solvate thereof, is administered in a form of a food or drink.
11. The method according to claim 3 , wherein said peptide, pharmaceutically acceptable salt, or solvate thereof, is administered in a form of a food or drink.
12. The method according to claim 4 , wherein said peptide, pharmaceutically acceptable salt, or solvate thereof, is administered in a form of a food or drink.
13. The method according to claim 1 , wherein said peptide, pharmaceutically acceptable salt, or solvate thereof, is administered in a form of a pharmaceutical.
14. The method according to claim 2 , wherein said peptide, pharmaceutically acceptable salt, or solvate thereof, is administered in a form of a pharmaceutical.
15. The method according to claim 3 , wherein said peptide, pharmaceutically acceptable salt, or solvate thereof, is administered in a form of a pharmaceutical.
16. The method according to claim 4 , wherein said peptide, pharmaceutically acceptable salt, or solvate thereof, is administered in a form of a pharmaceutical.